Abstract
The present study was to investigate the clinical significance of peroxiredoxin 2 (PRDX2), an oncoenzyme, in the development and progression of colorectal cancer(CRC).We found levels of PRDX2 mRNA and protein were higher in CRC cell lines than in normal human colonic epithelial cells. PRDX2 expression was significantly up-regulated in CRC lesions compared with that in the adjacent noncancerous tissues. CRC tissues from 148 of 226 (65.5%) patients revealed high level of PRDX2 protein expression in contrast to only 13 of 226 (5.8%) PRDX2 strong staining cases in the adjacent noncancerous tissues. Increased expression of PRDX2 protein was significantly associated with poor tumor differentiation (p = 0.001), advanced local invasion (p = 0.046), increased lymph node metastasis (p = 0.008), and advanced TNM stage (p = 0.020). Patients with higher PRDX2 expression had a significantly shorter disease-free survival and worse disease-specific survival than those with low expression. Importantly, PRDX2 up-regulation was an independent prognostic indicator for stage I–III, early stage (stage I-II) and advanced stage (stage III) patients. In conclusion, our findings suggest PRDX2 up-regulation correlates with tumor progression and could serve as a useful marker for the prognosis of CRC.
Highlights
Colorectal cancer (CRC) is a common malignant disease with high morbidity and mortality [1]
The present study was to investigate the clinical significance of peroxiredoxin 2 (PRDX2), an oncoenzyme, in the development and progression of colorectal cancer(CRC).We found levels of PRDX2 mRNA and protein were higher in CRC cell lines than in normal human colonic epithelial cells
We found that all colorectal cancer cell lines revealed higher PRDX2 mRNA expression compared with those in human colonic epithelial cells (HCEC) (Figure 1B)
Summary
Colorectal cancer (CRC) is a common malignant disease with high morbidity and mortality [1]. The clinical stage of CRC is the main indicator to assess the prognosis of patients, clinical outcome differs greatly even among patients of the same tumor–node–metastasis (TNM) stage [5]. Over-expression of PRDX2 has been reported in various cancer tissues and cells, which is essential for tumor maintenance and survival by protecting cells against ROS injury and apoptosis [12,13,14,15]. Inhibiting PRDX2 expression decreased the growth of breast cancer metastatic cells in lungs [19]. Take together, these findings suggest that PRDX2 is closely associated with the proliferation, metastasis, radio-resistance and drugresistance of cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
